Patterns Of Care
HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:58:36
- Mais informações
Informações:
Sinopse
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. CME information and select publications here.
